Mikhail M, Kennedy R, Cramer B, Smith T
Dr Charles A. Janeway Child Health Centre, St John's, Newfoundland.
J Pediatr Surg. 1995 Aug;30(8):1159-60. doi: 10.1016/0022-3468(95)90011-x.
The authors present two cases of lymphangioma of the cervicofacial region, treated with a new investigational drug in North America, OK-432 (picibanil), a sclerosing agent intralesionally injected. Both patients had been treated surgically and had recurrence of the tumor. Intralesional injection of OK-432 without aspiration was employed for the first patient, and after aspiration in the second patient. A change in consistency of the tumor, manifested by softening, was followed by marked shrinkage. No complication either locally or systemically has occurred during the follow-up period (10 to 16 months). In both cases, satisfactory results were obtained, resulting in definite reduction in size and improvement in cosmetic appearance. The authors recommend OK-432 intralesional injection for surgically challenging lymphangioma. Their results support those of a recent Japanese study using OK-432 as sclerosing therapy for unresectable lymphangioma.
作者报告了两例颈面部淋巴管瘤患者，在北美接受了一种新型研究药物OK-432（溶链菌制剂）的治疗，该药物为一种硬化剂，通过瘤内注射给药。两名患者均接受过手术治疗，但肿瘤复发。第一例患者未进行抽液直接进行瘤内注射OK-432，第二例患者则在抽液后进行注射。肿瘤质地出现改变，表现为变软，随后显著缩小。随访期间（10至16个月）未出现局部或全身并发症。两例患者均取得了满意的效果，肿瘤大小明显缩小，外观改善。作者推荐对手术治疗有挑战性的淋巴管瘤采用OK-432瘤内注射治疗。他们的结果支持了日本最近一项使用OK-432作为不可切除淋巴管瘤硬化治疗的研究结果。
